Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Priorities and Implementation Barriers in End-to-End Digital Transformation in the Pharmaceutical Industry: Sequential Mixed Methods Analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
New estimates on the cost of a delay day in drug development
10.1007/s43441-024-00667-w · External reference
New benchmarks characterizing growth in protocol design complexity
10.1177/2168479017713039 · External reference
Assessing the impact of protocol design changes on clinical trial performance
10.1097/mjt.0b013e31816b9027 · External reference
The impact of protocol amendments on clinical trial performance and cost
10.1177/2168479016632271 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Applications of machine learning in drug discovery and development
10.1038/s41573-019-0024-5 · External reference
Empowering clinical research in a decentralized world
10.1038/s41746-021-00473-w · External reference
Assessing the net financial benefits of employing digital endpoints in clinical trials
10.1111/cts.13902 · External reference
Digital transformation of the Pharmaceutical Industry: a future research agenda for management studies
10.1016/j.techfore.2024.123580 · External reference
The FAIR Guiding Principles for scientific data management and stewardship
10.1038/sdata.2016.18 · External reference
The FAIR Cookbook - the essential resource for and by FAIR doers
10.1038/s41597-023-02166-3 · External reference
Implementation and relevance of FAIR data principles in biopharmaceutical R&D
10.1016/j.drudis.2019.01.008 · External reference
Automating drug discovery
10.1038/nrd.2017.232 · External reference
High-performance medicine: the convergence of human and artificial intelligence
10.1038/s41591-018-0300-7 · External reference
A review on deep learning-driven drug discovery: strategies, tools and applications
10.2174/1381612829666230412084137 · External reference
Will artificial intelligence for drug discovery impact clinical pharmacology?
10.1002/cpt.1795 · External reference
AI enhances drug discovery and development
10.1093/nsr/nwad303 · External reference
Unleashing the power of generative AI in drug discovery
10.1016/j.drudis.2024.103992 · External reference
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
10.1007/s11030-021-10217-3 · External reference
Generative artificial intelligence empowers digital twins in drug discovery and clinical trials
10.1080/17460441.2023.2273839 · External reference
Artificial intelligence for drug discovery: are we there yet?
10.1146/annurev-pharmtox-040323-040828 · External reference
Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: a discussion of chemical and biological data
10.1016/j.drudis.2020.11.037 · External reference
Artificial intelligence in drug development: present status and future prospects
10.1016/j.drudis.2018.11.014 · External reference
Digital transformation: a multidisciplinary reflection and research agenda
10.1016/j.jbusres.2019.09.022 · External reference
The growing importance of mixed-methods research in health
10.3126/nje.v12i1.43633 · External reference
Achieving integration in mixed methods designs-principles and practices
10.1111/1475-6773.12117 · External reference
A process for conducting mixed methods data analysis
10.1002/jgf2.736 · External reference
Unresolved reference
External reference
Standards for reporting qualitative research: a synthesis of recommendations
10.1097/acm.0000000000000388 · External reference
The quality of mixed methods studies in health services research
10.1258/jhsrp.2007.007074 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Rigorous and rapid evidence assessment in digital health with the evidence DEFINED framework
10.1038/s41746-023-00836-5 · External reference
Unresolved reference
External reference
Beyond adoption: a new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies
10.2196/jmir.8775 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Data science in pharmaceutical R&D: the DISRUPT-DS industry roundtable
10.1038/d41573-024-00104-5 · External reference
Digitalization in pharmaceutical industry: what to focus on under the digital implementation process?
10.1016/j.ijpx.2021.100095 · External reference
Change management in hospital digital transformation: a roadmap to support planning and implementation for humanisation and efficiency through technology
10.1371/journal.pone.0344555 · External reference
Nature-based interventions targeting elderly people's health and well-being: an evidence map
10.3390/ijerph21010112 · External reference
Quantifying the use of connected digital products in clinical research
10.1038/s41746-020-0259-x · External reference
Unresolved reference
External reference
Harnessing real-world evidence for the development of novel cancer therapies
10.1016/j.trecan.2020.08.006 · External reference
Sharing historical trial data to accelerate clinical development
10.1002/cpt.1608 · External reference
10.1038/s41746-019-0090-4 · Admitted local publication
Adoption of artificial intelligence in the health care sector
10.1001/jamahealthforum.2025.5029 · External reference
